Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 EUR | -0.75% | 0.00% | +70.32% |
04-29 | Donaldson Agrees to Acquire 49% Stake in Medica | MT |
04-26 | Response Plus Unit Closes Prometheus Medical Acquisition | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 56 and 16.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+70.32% | 120M | - | ||
+24.77% | 48.09B | B- | ||
+47.30% | 40.62B | A | ||
-2.69% | 40.43B | B | ||
-6.95% | 28.36B | C | ||
+7.61% | 24.89B | B- | ||
-19.62% | 19.01B | B | ||
+28.86% | 12.09B | C+ | ||
-0.79% | 11.88B | B+ | ||
-0.62% | 11.8B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MDC Stock
- Ratings Medica S.p.A.